ProUroCare Medical to Attend 25th Anniversary EAU Congress in Barcelona
MINNEAPOLIS, April 15 /PRNewswire-FirstCall/ — ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD, PUMDU and PUMDW), a provider of proprietary medical imaging products, today announces that it will be attending the European Association of Urology (EAU) Congress in Barcelona, Spain, April 16-20. This year’s EAU will hold a special roundtable press event to address prostate cancer screening issues and processes for improving early detection. ProUroCare plans to engage and inform European physicians and health influencers about its patented prostate imaging and data storage system.
The company’s innovative ProUroScan system is currently under review by the FDA. The company’s diagnostic technology is intended to aid physicians in visualizing and documenting prostate abnormalities also detected by Digital Rectal Exam (DRE).
“Prostate cancer is a major global health problem, but its prevalence and the standards of care vary among different countries,” said Rick Carlson, CEO of ProUroCare. “The EAU Congress offers a great chance to interface with physician thought leaders and distributors in the European health care community.”
Over the last 25 years, the EAU has consistently strived to improve patient care worldwide. The Anniversary EAU Congress in Barcelona expects to attract more than 11,000 delegates and approximately 3,000 company representatives.
About ProUroCare Medical, Inc.
ProUroCare Medical, Inc. is a publicly traded company engaged in the business of creating innovative medical imaging products. The company’s current focus is the ProUroScan prostate imaging system, which is used to map abnormalities of the prostate detected by DRE. Based in Minneapolis, Minn., ProUroCare is traded on the OTCBB.
Safe Harbor Statement
This news release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements are not guarantees of ProUroCare’s future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare’s results to differ materially from those expressed or implied by such forward-looking statements are detailed from time to time in ProUroCare’s filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q.
SOURCE ProUroCare Medical, Inc.